

Interim Report

January–March 2026

1 January–31 March 2026

- Net sales amounted to SEK 4,521m (3,995), up 13%.
- Adjusted EBITA amounted to SEK 442m (364), up 21%.
- The adjusted EBITA margin was 9.8% (9.1).
- EBIT amounted to SEK 310m (237), and profit for the quarter amounted to SEK 197m (95).
- Earnings per share before and after dilution amounted to SEK 0.50 (0.19).
- Return on net working capital (EBITA/NWC) amounted to 67.7% (66.5).
- Cash flow from operating activities amounted to SEK 419m (109).
- During the quarter, Asker signed two acquisition agreements: GHC/MPF (Germany) and RMS Medical Devices (Belgium).



Strong start to the year with solid performance across the entire Group. 5% organic sales growth, 8% organic adjusted EBITA growth, increased EBITA margin and robust cash flow. Two new acquisitions signed, with maintained leverage and room for further acquisitions during the year.



Key performance indicators

| Amounts in SEKm, unless otherwise stated | 1 January–31 March | | | Rolling 12 months | Full-year |
|---|--------------------|-------|----------|-------------------|-----------|
| | 2026 | 2025 | Change | 2025/2026 | 2025 |
| Net sales | 4,521 | 3,995 | 13% | 17,312 | 16,787 |
| Adjusted EBITA* | 442 | 364 | 21% | 1,672 | 1,594 |
| Adjusted EBITA margin, %* | 9.8% | 9.1% | 0.7 p.p. | 9.7% | 9.5% |
| EBITA* | 428 | 311 | 38% | 1,507 | 1,390 |
| EBITA margin, %* | 9.5% | 7.8% | 1.7 p.p. | 8.7% | 8.3% |
| EBIT | 310 | 237 | 31% | 1,082 | 1,009 |
| Profit for the period | 197 | 95 | 107% | 612 | 510 |
| Earnings per share before and after dilution (SEK) | 0.50 | 0.19 | 172% | 1.55 | 1.25 |
| Earnings per share before and after dilution (SEK), adjusted* | 0.50 | 0.24 | 112% | 1.55 | 1.28 |
| Net debt/EBITDA** | 2.15 | 1.70 | 0.45x | 2.15 | 2.26 |
| Return on net working capital (EBITA/NWC), %* | 67.7% | 66.5% | 1.1 p.p. | 67.7% | 67.0% |
| Cash flow from operating activities | 419 | 109 | 284% | 1,637 | 1,328 |

* Refer to Note 5 for the calculation of alternative performance measures and the definitions section for further information about these performance indicators.

** EBITDA rolling 12 months adjusted for leases and items affecting comparability.

CEO'S COMMENTS

Strong start to the year

The year began with continued high activity and good organic growth across the entire Group. Sales increased by 5% organically and 13% overall. Adjusted EBITA increased by 8% organically and 21% overall. More customers, an expanded product range, implemented efficiency enhancements, economies of scale and the acquisitions of recent years all contributed to a margin increase of 0.7 percentage points to 9.8%. We continued our acquired growth by signing two new acquisitions during the quarter, while keeping our leverage below our financial target.

Growth and margin improvement that rests on a stable and broad foundation

The organic growth rate remained favourable across the Group. Our aim is to increase our sales at a pace that is slightly faster than market growth of 3–4% and adjusted EBITA slightly faster than that, which we accomplished in the first quarter. The conflict in the Middle East has not had any negative impact on our operations. With the lessons learned from the pandemic fresh in our mind, we mobilised early and actively utilised our good supplier relationships, enabling us to secure the necessary volumes. Nonetheless, we are monitoring developments closely.

The improvement in growth and margin is based on a solid and broad foundation, with all regions reporting a good performance. The combination of good sales growth, ongoing efficiency enhancements and economies of scale is driving the organic development. This is being supported by companies we have owned for a long time as well as our newly acquired companies. Sales and earnings were negatively impacted by exchange rate effects of –4% due to the weaker USD and EUR against the SEK.

The solid organic earnings performance, acquisitions in 2025 and efficient working capital management contributed to the strengthened operating cash flow, which increased to SEK 419m.

Good organic growth in all business areas

During the quarter, Business Area West once again demonstrated strong growth, not least in terms of earnings, with the effects of economies of scale from an increasingly large business having an impact. The direct-to-patient business in the Netherlands has grown from 80,000 patients in 2015 to more than 570,000 patients today who receive advice and products from the team on a daily basis to meet their healthcare needs. While some of this patient growth is derived from acquisitions, a large part is organic. This is clear evidence that their continuous efforts to put patients front and centre represent a key success factor in both attracting new patients and retaining them over time.

Business Area Central continued to deliver significant EBITA growth, up +47%. They are maintaining a high pace in

terms of acquisitions, and systematic efforts to progressively improve the product mix and phase out less attractive products and categories are clearly reflected in the organic profit growth.


Business Area North continued to deliver stable growth with good margins, and now the major defence and preparedness contracts are no longer included in the comparative figures.

Two acquisitions

During the quarter, we signed two new acquisitions: the inter-linked companies German Healthcare and Medicalprodukte Vertrieb Flensburg (GHC/MPF), and RMS Medical Devices (RMS). GHC/MPF is active in medical supplies for the German home care market and RMS is a fast-growing medical device distributor based in Belgium. The two acquisitions strengthen and complement our existing offering in Central and West.

Cash flow invested in new acquisitions

Demand for medical products is stable, providing us with good visibility for the remainder of the year. We have established a clear plan for investing our strong and stable cash flows in new, high-quality companies. In parallel, we are constantly striving to identify more efficient ways to run our business and to seek out new opportunities for cooperation between companies and across borders to capitalise on the economies of scale generated by our larger size. We are also seeing growing interest from global suppliers to partner with us in Europe. As always, our goal for 2026 is to exceed our customers' expectations and deliver on our financial targets.



Johan Falk,
CEO

Financial performance – Group

Net sales

Net sales for the first quarter amounted to SEK 4,521m (3,995), up 13% year-on-year, of which 5% was organic growth, 12% from acquisitions and exchange rates had a negative impact of 4%. Sales growth was driven by a favourable organic performance across the Group and the completion of acquisitions in the Business Areas West and Central.

Adjusted EBITA, net financial items and profit for the period

Adjusted EBITA for the first quarter amounted to SEK 442m (364), up 21%, of which 8% was organic growth, 17% from acquisitions and exchange rates had a negative impact of 4%. Both established and newly acquired companies supported the growth and margin improvement. The adjusted EBITA margin was 9.8% (9.1) for the first quarter.

EBIT amounted to SEK 310m (237). The higher year-on-year EBIT was the result of growth, lower acquisition costs, lower revaluation effects related to contingent considerations and costs for the IPO in March 2025 impacting the corresponding quarter of the preceding year. Net financial items for the first quarter amounted to SEK –53m (–104). The year-on-year decrease was primarily due to lower interest expenses – partly because former shareholder loans were converted into equity in connection with the IPO – and to unrealised exchange rate gains on derivatives. Tax for the first quarter amounted to SEK –60m (–39), corresponding to an effective tax rate of 23% (29). Profit for the period amounted to SEK 197m (95) for the first quarter.

Financial position and cash flow

Cash flow from operating activities for the first quarter amounted to SEK 419m (109). The increased cash flow for the quarter was primarily the result of favourable earnings growth and efficient working capital management. Net debt increased to SEK 3,871m (2,585). Net debt in relation to adjusted EBITDA amounted to 2.15x (1.70). The acquisitions completed during the quarter include terms under which parts of the purchase price will be paid later in 2026. Including these, net debt in relation to adjusted EBITDA amounted to 2.25x, on par with the preceding quarter. Return on net working capital (EBITA/NWC) was in line with the preceding year at 67.7% (66.5). At the end of the quarter, cash and cash equivalents amounted to SEK 945m (735) and undrawn credit facilities to SEK 994m (1,506).


Items affecting comparability

Items affecting comparability amounted to SEK 13m (53) for the first quarter, of which SEK 10m (22) was related to acquisition and integration expenses and SEK 3m (16) to revaluations of contingent considerations. The year-on-year difference was also the result of IPO-related items affecting comparability last year.


Earnings per share

Profit for the period attributable to the Parent Company’s shareholders amounted to SEK 193m (91) for the first quarter. Earnings per share before and after dilution amounted to SEK 0.50 (0.19). The average number of common shares outstanding, before and after dilution, used in the calculation of earnings per share was 383,036,497 for the first quarter and 323,882,934 for the first quarter of 2025. Refer to Note 5 for a reconciliation and calculation. At the end of the period, the number of common shares outstanding totalled 383,036,497.


Net sales per quarter




Adjusted EBITA per quarter



Adjusted EBITA growth Jan-Mar 2026




Financial targets and rolling 12-month outcomes



* EBITDA rolling 12 months adjusted for expenses attributable to leases and items affecting comparability.

Progress towards 2030 sustainability targets is on track



* Reduced Scope 1 and 2 emissions as a percentage compared to the 2021 base year, market-based.

** Total Scope 3, category 1 emissions per SEK m gross profit (tCO₂e/SEK m).


*** Percentage of suppliers, based on sales, that have signed Asker's Code of Conduct or an equivalent code.

For all sustainability targets, refer to the 2025 Annual Report.

Financial performance – Business areas

Asker Healthcare Group focuses on northern, western and central Europe and currently has a presence in 19 countries. The Group also has a quality and audit office in Asia. The Group’s operations are conducted in three business areas defined by geographical market, comprising North, West and Central.

Net sales per segment, LTM, 1 April 2025 – 31 March 2026



Business Area North

North consists of Sweden, Norway, Finland, Estonia, Latvia and Lithuania. Operations are conducted through 18 subsidiaries. The average number of full-time equivalents during the quarter was 879 (822).


Financial performance

Net sales for the first quarter amounted to SEK 1,354m (1,263), up 7%, of which 7% was organic, 2% from acquisitions and exchange rates had a negative impact of 2%. Adjusted EBITA for the first quarter amounted to SEK 186m (177), up 5%, and the adjusted EBITA margin amounted to 13.7% (14.0).

The businesses in North continued to perform well in the first quarter, delivering good organic growth. In Gothenburg, work on completing the new distribution centre progressed according to plan, with testing of the facility conducted in early April showing good results.

Evercare Medical received Nordic Swan Ecolabel certification for the Embra Gravity Set, the first gravity infusion set on the market to receive an ecolabel. Sustainability criteria are becoming an increasingly important part in procurements of Nordic customers, which resulted in further tender wins during the quarter.

Adjusted EBITA growth – North Jan–Mar 2026



| Amounts in SEKm | 1 January–31 March | | | Rolling 12 months | Full-year |
|--------------------------|--------------------|-------|-----------|-------------------|-----------|
| | 2026 | 2025 | Change | 2025/2026 | 2025 |
| Net sales | 1,354 | 1,263 | 7% | 5,301 | 5,210 |
| Adjusted EBITA | 186 | 177 | 5% | 690 | 681 |
| Adjusted EBITA margin, % | 13.7% | 14.0% | -0.3 p.p. | 13.0% | 13.1% |

Business Area West

West consists of the Netherlands, Belgium, Luxembourg, the UK, Ireland and Denmark. Operations are conducted through 17 subsidiaries. The average number of full-time equivalents during the quarter was 2,072 (1,976).

Financial performance


Net sales in the first quarter amounted to SEK 2,254m (2,008), up 12%, of which 5% was organic growth, 12% from acquisitions and exchange rates had a negative impact of 5%. Adjusted EBITA for the first quarter amounted to SEK 213m (161), up 32%, and the adjusted EBITA margin amounted to 9.5% (8.0).

Business Area West performed well during the quarter, reporting good organic and acquisition-led growth. The trend in home care was particularly strong, with the business area's operations continuing to generate further growth and realise economies of scale.

The business area's position in diabetes care as well as incontinence and wound care was further strengthened by the acquisition of Van Heek Medical, which was completed in February. After the end of the quarter, the acquisition of RMS Medical Devices, which implements innovative medical technologies into hospitals across the Benelux region, was also completed.

Adjusted EBITA growth – West

Jan–Mar 2026



| Amounts in SEKm | 1 January–31 March | | | Rolling 12 months | Full-year |
|--------------------------|--------------------|-------|----------|----------------------|-----------|
| | 2026 | 2025 | Change | 2025/2026 | 2025 |
| Net sales | 2,254 | 2,008 | 12% | 8,789 | 8,543 |
| Adjusted EBITA | 213 | 161 | 32% | 810 | 757 |
| Adjusted EBITA margin, % | 9.5% | 8.0% | 1.5 p.p. | 9.2% | 8.9% |

Business Area Central

Central consists of France, Germany, Austria, Switzerland, Slovakia, Poland and the Czech Republic. Operations are conducted through 17 subsidiaries. The average number of full-time equivalents during the quarter was 1,000 (755).

Financial performance


Net sales for the first quarter amounted to SEK 913m (725), up 26%, of which 3% was organic, 27% from acquisitions and exchange rates had a negative impact of 4%. Adjusted EBITA for the first quarter amounted to SEK 80m (54), up 47%, and the adjusted EBITA margin amounted to 8.8% (7.5).

The sustained strong sales and EBITA growth was supported by all countries. Both companies that have been part of the Group for a longer period of time and more recent acquisitions contributed to growth, through a combination of a greater number of products, new customer categories and operational efficiencies. The business area continued to concentrate on margin-enhancing activities, which included gradually phasing out low-margin products.

The acquisition of GHC/MPF was completed during the quarter, strengthening the business area's position in home care in Germany.

Adjusted EBITA growth – Central

Jan–Mar 2026



| Amounts in SEKm | 1 January–31 March | | | Rolling 12 months | Full-year |
|--------------------------|--------------------|------|----------|----------------------|-----------|
| | 2026 | 2025 | Change | 2025/2026 | 2025 |
| Net sales | 913 | 725 | 26% | 3,222 | 3,034 |
| Adjusted EBITA | 80 | 54 | 47% | 284 | 259 |
| Adjusted EBITA margin, % | 8.8% | 7.5% | 1.3 p.p. | 8.8% | 8.5% |

Other information

Employees

During the quarter, full-time equivalents in the Group averaged 3,999 (3,554), of which the Group function had 48 (45) full-time equivalents. The number of employees amounted to 4,781 (4,238) at the end of the quarter and 4,580 at the beginning of the quarter.

Parent Company

Asker Healthcare Group AB (559184-9848) is the Parent Company of the Group. Net sales for the Parent Company amounted to SEK 4m (4) for the first quarter. Net financial items amounted to SEK 0m (42) and loss before tax was SEK –8m (23). Total assets amounted to SEK 7,737m (7,990) and total liabilities to SEK 3,259m (3,444). The Parent Company has 2 (2) employees.

Accounting policies

This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting, the Swedish Corporate Reporting Board's recommendation RFR 1 and the Swedish Annual Accounts Act. The information submitted in accordance with IAS 34.16A has been presented both in the consolidated financial statements and in other sections of this interim report. The interim report is presented in million Swedish kronor (SEKm) unless otherwise stated. Amounts in parenthesis refer to the preceding year. There may be differences in totals since individual items have been rounded to the nearest whole SEKm. The accounting policies have been applied as described in the Group's 2025 Annual Report.

None of the amendments to IFRS accounting standards that entered force during the year had any material impact on the consolidated financial statements. For more information, refer to the disclosures as described in the Group's 2025 Annual Report.

The Parent Company's financial statements have been prepared in accordance with the Swedish Corporate Reporting Board's recommendation RFR 2 Accounting for Legal Entities and the Swedish Annual Accounts Act. RFR 2 means that the Parent Company for the legal entity is to apply all IFRS accounting standards and statements as adopted by the EU as far as possible within the framework of the Annual Accounts Act and taking into account the relationship between accounting and taxation.

Estimates and judgments

There have been no changes in the estimates and judgments described in the Group's most recently issued Annual Report for 2025.

Material risks and uncertainties

The Group's strategic and operational position, and the expected trend in its earnings and financial position, may be affected by risks and uncertainties that the Group is exposed to. Asker works continuously to identify and monitor risks so that it can leverage opportunities to achieve business targets or counter-act such risks that the Group is unwilling to take. The material risks that are deemed to have the greatest impact on the Group are strategic and operational risks related to geopolitics and disruptions to the global supply chain, IT and information security-related risks and financial stability. In addition, the Group is impacted by financial risks such as currency risks, liquidity risks and refinancing risks.

Changes to risk during the quarter

The general uncertainty in global markets remains high. Company management is closely following developments and mitigation plans are followed up and adjusted as necessary. Increasing geopolitical unrest could disrupt supply chains, but the geopolitical situation did not impact the Group's financial position during the quarter. For more information on the Group's risks, refer to the risk section in the Group's Annual Report for 2025.

Annual General Meeting 2026

Notice to the Annual General Meeting of Asker Healthcare Group AB was published on 30 March 2026. The Annual General Meeting will be held on Thursday, 7 May 2026, at 1:30 p.m. at Näringslivets Hus, Storgatan 19, SE-114 51 Stockholm.

The Nomination Committee has proposed that Mikael Stöhr be elected as new Chair and member of the Board of Directors, and that Joachim Zetterlund be elected as new member of the Board. Asker's current Chair of the Board, Håkan Björklund, has declined re-election. Board member Martin Lagerblad has also declined re-election. The Nomination Committee proposes re-election of the other Board members Birgitta Stymne Göransson, Karl Petersson, Mikael Vinje and Nina Linander.

Issuance, repurchase and reclassification of Class C shares

On 9 March 2026, the Board of Directors of Asker resolved to issue 670,000 new Class C shares and to immediately thereafter repurchase and reclassify all of the issued Class C shares into ordinary shares. The purpose of the issuance, repurchase and reclassification is to ensure the delivery of ordinary shares to employees within the Asker Group in accordance with Asker's long-term performance-based investment share programme. As of 31 March 2026, Asker holds 670,000 treasury shares.

Danderyd, 6 May 2026

Johan Falk
CEO

This report has not been reviewed by Asker Healthcare Group's auditors.
This report is published in Swedish and English. The Swedish version is the original version.



Financial statements – Group

Consolidated income statement

| Amounts in SEKm | Note | 1 January–31 March | | Full-year |
|--|------|--------------------|--------------|--------------|
| | | 2026 | 2025 | 2025 |
| Net sales | 2 | 4,521 | 3,995 | 16,787 |
| Cost of goods sold | | -2,657 | -2,367 | -9,916 |
| Gross profit | | 1,864 | 1,629 | 6,871 |
| Selling expenses | | -1,093 | -969 | -4,119 |
| Administrative expenses | | -473 | -409 | -1,680 |
| Other operating income | | 19 | 8 | 54 |
| Other operating expenses | | -7 | -21 | -117 |
| Operating profit (EBIT) | | 310 | 237 | 1,009 |
| Financial income | | 95 | 167 | 222 |
| Financial expenses | | -148 | -271 | -572 |
| Profit before tax | | 257 | 134 | 659 |
| Income tax | | -60 | -39 | -149 |
| Profit for the period | | 197 | 95 | 510 |
| Profit attributable to: | | | | |
| Parent Company's shareholders | | 193 | 91 | 492 |
| Non-controlling interests | | 4 | 4 | 18 |
| Earnings per share before and after dilution (SEK) | 5 | 0.50 | 0.19 | 1.25 |

Condensed consolidated statement of comprehensive income

| Amounts in SEKm | 1 January–31 March | | Full-year |
|---|--------------------|-------------|-------------|
| | 2026 | 2025 | 2025 |
| Profit for the period | 197 | 95 | 510 |
| Other comprehensive income for the period | | | |
| <i>Items that have been or can be reclassified to the income statement</i> | | | |
| Translation differences for the period on translation of foreign operations | 83 | -220 | -276 |
| Total other comprehensive income for the period | 83 | -220 | -276 |
| Comprehensive income for the period | 280 | -125 | 234 |
| Of which, attributable to: | | | |
| Parent Company's shareholders | 276 | -128 | 216 |
| Non-controlling interests | 4 | 2 | 18 |

Condensed consolidated balance sheet

| Amounts in SEKm | Note | 31 March | | 31 December |
|--|------|---------------|---------------|---------------|
| | | 2026 | 2025 | 2025 |
| ASSETS | | | | |
| Goodwill | | 6,635 | 5,553 | 6,369 |
| Other intangible assets | | 3,230 | 2,278 | 3,027 |
| Tangible assets | | 1,888 | 1,435 | 1,780 |
| Financial non-current assets | | 50 | 28 | 32 |
| Deferred tax assets | | 97 | 81 | 94 |
| Total non-current assets | | 11,900 | 9,376 | 11,302 |
| Inventories | | 2,183 | 1,880 | 2,041 |
| Accounts receivable | | 2,153 | 1,768 | 2,052 |
| Other current receivables | | 572 | 475 | 495 |
| Cash and cash equivalents | | 945 | 735 | 884 |
| Total current assets | | 5,853 | 4,859 | 5,472 |
| TOTAL ASSETS | | 17,753 | 14,234 | 16,774 |
| EQUITY AND LIABILITIES | | | | |
| Equity attributable to Parent Company's shareholders | | 6,833 | 6,206 | 6,555 |
| Non-controlling interests | | 38 | 32 | 33 |
| Total equity | | 6,871 | 6,239 | 6,588 |
| Interest-bearing liabilities | 3 | 4,242 | 3,321 | 4,224 |
| Lease liabilities | | 766 | 677 | 727 |
| Deferred tax liabilities | | 666 | 503 | 606 |
| Other non-current liabilities and provisions | 3 | 730 | 691 | 591 |
| Total non-current liabilities | | 6,405 | 5,193 | 6,149 |
| Interest-bearing liabilities | 3 | 686 | 1 | 557 |
| Lease liabilities | | 324 | 241 | 306 |
| Accounts payable | | 1,698 | 1,363 | 1,610 |
| Other current liabilities | 3 | 1,769 | 1,197 | 1,565 |
| Total current liabilities | | 4,477 | 2,802 | 4,038 |
| TOTAL EQUITY AND LIABILITIES | | 17,753 | 14,234 | 16,774 |

Condensed consolidated statement of changes in equity

| Amounts in SEKm | 1 January–31 March | | Full-year |
|--|--------------------|--------------|--------------|
| | 2026 | 2025 | 2025 |
| Opening balance | 6,588 | 3,486 | 3,502 |
| Comprehensive income for the period | 280 | -125 | 234 |
| Paid share issue* | – | 1,440 | 1,426 |
| Set-off issue* | – | 1,439 | 1,439 |
| Investment share programme | 3 | – | 4 |
| Dividends paid to non-controlling interests | – | – | -15 |
| Transactions attributable to non-controlling interests | – | -1 | -1 |
| Closing balance | 6,871 | 6,239 | 6,588 |
| Equity attributable to: | | | |
| Parent Company's shareholders | 6,833 | 6,206 | 6,555 |
| Non-controlling interests | 38 | 32 | 33 |

* In conjunction with the IPO on 27 March 2025, Asker conducted a new share issue totalling SEK 1,500m, consisting of 21,428,571 shares at a subscription price of SEK 70 per share. Transaction costs for the full-year amounted to SEK 93m, which, net of tax, impacted equity in the amount of SEK 1,426m. In parallel, a directed set-off issue was conducted to repay existing shareholder loans. The value of shareholder loans with accrued interest amounted to SEK 1,439m, meaning that 20,552,600 new shares were issued at a subscription price of SEK 70 per share.

Condensed consolidated statement of cash flows

| Amounts in SEKm | Note | 1 January–31 March | | Full-year |
|---|------|--------------------|--------------|---------------|
| | | 2026 | 2025 | 2025 |
| Operating profit (EBIT) | | 310 | 237 | 1,009 |
| Adjustments for non-cash items* | | 239 | 187 | 839 |
| Interest received | | 1 | 3 | 10 |
| Interest paid | | -56 | -59 | -201 |
| Income tax paid | | -62 | -132 | -337 |
| | | 433 | 236 | 1,321 |
| Change in current receivables | | -50 | -14 | -87 |
| Change in inventories | | -5 | -13 | 53 |
| Change in current liabilities | | 41 | -100 | 41 |
| Cash flow from operating activities | | 419 | 109 | 1,328 |
| Investments in intangible and tangible assets | | -101 | -72 | -590 |
| Sale of intangible and tangible assets | | 4 | - | 15 |
| Acquisition of subsidiaries (less acquired cash) | 4 | -168 | -833 | -2,331 |
| Cash flow from investing activities | | -265 | -904 | -2,906 |
| New borrowings | | - | 4,104 | 5,098 |
| Repayments of borrowings | | - | -4,037 | -4,258 |
| Repayment of lease liabilities | | -83 | -66 | -290 |
| Changes in overdraft facilities | | -20 | -372 | 59 |
| Share issue | | - | 1,425 | 1,407 |
| Private placement for non-controlling interests | | - | 24 | 24 |
| Dividends paid to holders of non-controlling interests | | - | -1 | -15 |
| Cash flow from financing activities | | -103 | 1,077 | 2,025 |
| Cash flow for the period | | 50 | 282 | 447 |
| Cash and cash equivalents at the beginning of the period | | 884 | 490 | 490 |
| Exchange rate differences in cash and cash equivalents | | 11 | -37 | -53 |
| Cash and cash equivalents at the end of the period | | 945 | 735 | 884 |

* Pertains mainly to amortisation and revaluation of contingent considerations.

Condensed income statement for the Parent Company

| Amounts in SEKm | 1 January–31 March | | Full-year |
|-------------------------------------|--------------------|------------|------------|
| | 2026 | 2025 | 2025 |
| Net sales | 4 | 4 | 19 |
| Gross profit | 4 | 4 | 19 |
| Administrative expenses | -12 | -23 | -53 |
| Other operating income and expenses | - | 0 | 1 |
| Operating loss | -9 | -19 | -34 |
| Financial income and expenses | 0 | 42 | 67 |
| Appropriations | - | - | 43 |
| Profit/loss before tax | -8 | 23 | 76 |
| Income tax | 2 | 0 | -19 |
| Profit/loss for the period | -7 | 23 | 58 |

The Parent Company has no transactions to report in other comprehensive income, and subsequently the Parent Company's comprehensive income is consistent with profit/loss for the period.

Condensed balance sheet for the Parent Company

| Amounts in SEKm | 31 March | | 31 December |
|-------------------------------------|--------------|--------------|--------------|
| | 2026 | 2025 | 2025 |
| ASSETS | | | |
| Financial non-current assets | 3,583 | 3,573 | 3,578 |
| Total non-current assets | 3,583 | 3,573 | 3,578 |
| Current assets | 4,153 | 4,402 | 4,176 |
| Cash and cash equivalents | 1 | 14 | 0 |
| Total current assets | 4,154 | 4,417 | 4,176 |
| TOTAL ASSETS | 7,737 | 7,990 | 7,754 |
| EQUITY AND LIABILITIES | | | |
| Restricted equity | 1 | 1 | 1 |
| Non-restricted equity | 4,466 | 4,446 | 4,470 |
| Total equity | 4,466 | 4,446 | 4,470 |
| Untaxed reserves | - | 91 | - |
| Provisions | 11 | 9 | 11 |
| Non-current liabilities | 3,212 | 3,186 | 3,188 |
| Current liabilities | 47 | 257 | 84 |
| Total liabilities | 3,259 | 3,444 | 3,273 |
| TOTAL EQUITY AND LIABILITIES | 7,737 | 7,990 | 7,754 |

Notes

NOTE 1 Segment information

| Amounts in SEKm | 1 January–31 March | | Full-year |
|--|--------------------|--------------|---------------|
| | 2026 | 2025 | 2025 |
| Net sales from external customers | | | |
| North | 1,354 | 1,263 | 5,210 |
| West | 2,254 | 2,008 | 8,543 |
| Central | 913 | 725 | 3,034 |
| Other and eliminations | – | – | – |
| Total net sales from external customers | 4,521 | 3,995 | 16,787 |
| Net sales from other operating segments | | | |
| North | 22 | 23 | 93 |
| West | 19 | 12 | 72 |
| Central | 4 | 2 | 11 |
| Other and eliminations | –44 | –38 | –175 |
| Total net sales from other operating segments | – | – | – |
| Total net sales | 4,521 | 3,995 | 16,787 |
| Adjusted EBITA | | | |
| North | 186 | 177 | 681 |
| West | 213 | 161 | 757 |
| Central | 80 | 54 | 259 |
| Other and eliminations | –37 | –28 | –102 |
| Total adjusted EBITA | 442 | 364 | 1,594 |
| Items affecting comparability (see definitions and Note 5) | –13 | –53 | –204 |
| EBITA | | | |
| North | 180 | 138 | 625 |
| West | 214 | 166 | 743 |
| Central | 72 | 64 | 185 |
| Other and eliminations | –38 | –57 | –163 |
| Total EBITA | 428 | 311 | 1,390 |
| Amortisation of intangible assets | –118 | –74 | –381 |
| Operating profit (EBIT) | 310 | 237 | 1,009 |
| Net financial items | –53 | –104 | –350 |
| Profit before tax | 257 | 134 | 659 |

NOTE 2 Net sales

Asker's companies primarily sell medical supplies, devices, equipment and related services, where some equipment requires installation. Two performance obligations have been identified in customer contracts comprising delivery of medical equipment that includes installation, since both the equipment and the installation are deemed to be distinct performance obligations. The performance obligation for the sale of medical

supplies, devices and equipment is satisfied when Asker's companies deliver the supplies and equipment in accordance with the delivery terms in the specific contract and control is thus transferred to the customer. Installation of medical equipment is a service that is recognised over time as it is performed. The same applies for service contracts.

| Amounts in SEKm | 1 January–31 March | | Full-year |
|-------------------------|--------------------|--------------|---------------|
| | 2026 | 2025 | 2025 |
| Sale of goods | | | |
| North | 1,222 | 1,138 | 4,697 |
| West | 2,055 | 1,855 | 7,855 |
| Central | 831 | 694 | 2,670 |
| Total goods | 4,107 | 3,687 | 15,223 |
| Sale of services | | | |
| North | 132 | 125 | 512 |
| West | 199 | 152 | 688 |
| Central | 82 | 31 | 364 |
| Total services | 414 | 309 | 1,564 |
| Total net sales | 4,521 | 3,995 | 16,787 |

NOTE 3 Fair value of financial instruments

Asker's financial assets and financial liabilities measured at fair value through profit or loss refer to derivatives and liabilities related to contingent considerations arising in connection with acquisitions. For derivatives, the fair value is determined based on observable market data, meaning level 2 of the fair value hierarchy stipulated in IFRS 13. The closing balance for positive derivatives amounted to SEK 28m (5), and the closing balance for negative derivatives amounted to SEK 10m (22). Liabilities for contingent considerations are recognised based on the acquired company's earnings, meaning a multiple valuation based on future EBITDA or EBITA performance measures, discounted using the Group's discount rate, with future EBITDA/

EBITA measures obtained from company management's best estimates based on adopted business plans, implying valuation in level 3 according to the fair value hierarchy. There were no transfers between levels during the period. Other assets and liabilities are recognised at amortised cost. The fair value of liabilities to credit institutions is estimated to be consistent with the carrying amount since the loans carry variable interest rates. The fair value of short-term borrowing corresponds to its carrying amount since the discount effect is not material. See below for a table of the changes in contingent considerations in level 3, from both business combinations and asset acquisitions.

| Contingent consideration | 31 March | | 31 December |
|---------------------------|--------------|------------|-------------|
| | 2026 | 2025 | 2025 |
| Amounts in SEKm | | | |
| Opening balance | 870 | 688 | 688 |
| Acquisitions | 134 | 52 | 215 |
| Payments | – | –16 | –166 |
| Remeasurement* | 3 | 16 | 96 |
| Discount effect* | 22 | 14 | 61 |
| Reclassifications | – | – | 8 |
| Exchange rate differences | 21 | –27 | –32 |
| Closing balance | 1,050 | 727 | 870 |

*The earnings effect of the remeasurement of contingent considerations amounts to SEK –3m (–16) and is recognised in other operating expenses. The impact of the discount effect is SEK –22m (–14) and is reported in net financial items.

NOTE 4 Business combinations

As part of Asker's value creation, whereby organic growth is complemented with acquisitions of small and medium-sized companies to add new products, customer groups and/or channels and thus build a full-service offering and create a platform for a more efficient value chain for the healthcare sector, the following business combinations have been completed in 2026.

- On 2 February, the Group acquired 100% of the shares in Van Heek Medical (signed in the fourth quarter of 2025), a leading manufacturer and distributor of medical supplies in the Benelux region. The company had 64 employees and a sales of approximately SEK 350m in the most recent financial year. Identified excess values consist of customer relationships, trademarks and goodwill.
- On 3 February, the Group acquired 100% of the shares in German Healthcare (GHC) and Medicalprodukte Vertrieb Flensburg (MPF), two interlinked medical supplies companies within the home care segment in Germany. The companies had 140 employees and sales of approximately SEK 300m in the most recent financial year. Identified excess values consist of customer relationships, trademarks and goodwill.

Preliminary purchase price allocations for acquired identifiable net assets are provided below. Since individual disclosures about acquisitions are not material, disclosures are provided in aggregated form.

Acquired assets measured at fair value

| Amounts in SEKm | Total for the period |
|--------------------------------------|----------------------|
| Intangible assets | 249 |
| Tangible assets | 6 |
| Right-of-use assets | 32 |
| Inventories | 110 |
| Other current assets | 97 |
| Cash and cash equivalents | 19 |
| Deferred tax assets/liabilities | -64 |
| Interest-bearing liabilities | -20 |
| Lease liabilities | -32 |
| Other operating liabilities | -90 |
| Total identifiable net assets | 308 |
| Goodwill | 201 |
| Non-controlling interests | - |
| Consideration | 509 |
| Paid consideration | 187 |
| Outstanding consideration 2026 | 187 |
| Contingent consideration | 134 |
| Total estimated consideration | 509 |

Effect of acquisitions on cash flow

| Amounts in SEKm | Total for the period |
|---|----------------------|
| Consideration | -187 |
| Cash and cash equivalents in acquired companies | 19 |
| Total impact on cash flow | -168 |

Other current assets mainly relate to accounts receivable. There is no material difference between acquired receivables and the gross amount, and there are no receivables that are not expected to be settled. Control was obtained through initial cash payments, forthcoming settlements of purchase considerations related to completed acquisitions, and contingent consideration agreements. Asker prepares preliminary purchase price allocations for the period during which there is uncertainty regarding the outcome of specific components of the acquisition agreements, for example, during the period that the company engages external valuation specialists and the external valuation has not yet been completed, or in cases when the final acquisition balance has not been received. However, the valuation period never extends for more than one year from the acquisition date. The purchase price allocations for acquisitions completed as of the second quarter of 2025 up to and including the first quarter of 2026 are preliminary since the Group has not received final, definitive information from the acquired companies. No material changes were made to the Group's purchase price allocations during the quarter with respect to acquisitions in the prior year.

Fair value adjustments to intangible assets generally comprise customer relationships, customer contracts and trademarks. Goodwill is justified based on high profitability and the personnel included in the acquired companies. For acquisitions, Asker usually applies an acquisition structure with basic consideration and possible contingent consideration. The contingent consideration is based on the earnings of the acquiree, implying a multiple valuation based on future EBITDA or EBITA performance measures, discounted using the Group's discount rate. Future EBITDA/EBITA performance measures are obtained from management's best estimate based on adopted business plans. Contingent consideration is initially measured at the present value of probable future outcomes, which for the acquisitions during the period has been estimated at SEK 134m (52). In total, contingent considerations for acquisitions completed during the period may amount to between SEK 0m and SEK 369m. No changes were made to the method for calculating consideration. Transaction costs for the acquisitions made during the period amounted to SEK 3m (16) and are included in administrative expenses in profit or loss.

The impact on the Group's net sales from the acquired companies since the acquisition date amounted to SEK 89m and the impact on the Group's EBITA since the acquisition date amounted to SEK 16m. If all acquired companies had been consolidated from 1 January 2026, net sales for the period would have amounted to SEK 4,569m and EBITA to SEK 433m.

Completed acquisitions after the end of the reporting period

- On 1 April, the Group acquired 100% of the shares in RMS Medical Devices (signed in the first quarter of 2026), a fast-growing medical device distributor based in Belgium. The company had 25 employees and sales of approximately SEK 170m in the most recent financial year. The purchase price allocation is ongoing and excess values are expected to consist of customer relationships, trademarks and goodwill.

Acquisitions signed, but not yet completed

- In May 2025, the Group signed an agreement on the acquisition of Kirstine Hardam, a leading distributor of medical supplies in Denmark. Sales amounted to approximately SEK 200m in 2024. The acquisition remains subject to regulatory approvals and the review is still ongoing.

NOTE 4 Business combinations, cont.**Acquisitions in the last two years**

| Year | Month of closure | Acquisitions | Business area | Country | Acquired shareholding | Net sales*, SEKm | No. of full-time equivalents |
|------|------------------|------------------|---------------|----------------|-----------------------|------------------|------------------------------|
| 2026 | February | GHC/MPF | Central | Germany | 100% | 300 | 117 |
| 2026 | February | Van Heek Medical | West | Netherlands | 100% | 350 | 59 |
| 2025 | December | Cardio Dépôt | Central | France | 100% | 25 | 5 |
| 2025 | November | Innomedicus | Central | Switzerland | 100% | 50 | 10 |
| 2025 | October | Novus Med | West | UK | 100% | 80 | 12 |
| 2025 | October | Finmed | Central | France | 79% | 380 | 62 |
| 2025 | October | Dartin | Central | Czech Republic | 100% | 46 | 23 |
| 2025 | September | Oudshoorn | West | Netherlands | 100% | 37 | 8 |
| 2025 | August | HNC | West | UK | 100% | 60 | 19 |
| 2025 | July | Scan Modul | West | Netherlands | 100% | 400 | 94 |
| 2025 | July | ITAK | North | Estonia | 100% | 90 | 67 |
| 2025 | May | MS Labors | Central | Austria | 100% | 23 | 5 |
| 2025 | February | HSL Group | West | Ireland | 97% | 800 | 150 |
| 2025 | February | Mayumana | West | Netherlands | 100% | 60 | 11 |
| 2024 | November | Hauser | Central | Austria | 100% | 23 | 5 |
| 2024 | November | Opitek | West | Denmark | 100% | 10 | 3 |
| 2024 | October | Kvinto | North | Norway | 100% | 60 | 3 |
| 2024 | September | Hugo | Central | UK | 100% | 81 | 84 |
| 2024 | August | Aspironix | Central | Czech Republic | 100% | 200 | 70 |
| 2024 | August | meetB | Central | Germany | 100% | 340 | 60 |
| 2024 | August | Funktionsverket | North | Sweden | 100% | 30 | 2 |
| 2024 | July | Wolturnus | West | Denmark | 100% | 150 | 71 |
| 2024 | March | Praximedico | Central | Switzerland | 100% | 60 | 12 |
| 2024 | February | Vegro | West | Netherlands | 95% | 820 | 586 |

* Estimated net sales at date of acquisition, annual basis

NOTE 5 Alternative performance measures

Certain information in Asker's interim report that is used by management and analysts to assess and evaluate the Group's financial position and earnings is not defined in accordance with IFRS Accounting Standards. The Group believes that the

information aids the understanding of Asker's financial position and earnings. This information should be regarded as supplementary information and does not replace the consolidated financial statements prepared in accordance with IFRS.

| Adjusted EBITA and adjusted EBITA margin, % | 1 January–31 March | | Rolling 12 months | Full-year |
|--|---------------------------|-------------|--------------------------|------------------|
| | 2026 | 2025 | 2025/2026 | 2025 |
| Amounts in SEKm | | | | |
| Operating profit (EBIT) | 310 | 237 | 1,082 | 1,009 |
| Amortisation of intangible assets from acquisitions | 89 | 55 | 323 | 288 |
| Amortisation of intangible assets from operating activities | 29 | 19 | 103 | 93 |
| EBITA | 428 | 311 | 1,507 | 1,390 |
| Items affecting comparability | | | | |
| Acquisition and integration expenses | 10 | 22 | 78 | 90 |
| Revaluation of contingent considerations | 3 | 16 | 83 | 96 |
| Other non-recurring items | – | 14 | 4 | 18 |
| Total items affecting comparability | 13 | 53 | 165 | 204 |
| Adjusted EBITA | 442 | 364 | 1,672 | 1,594 |
| Net sales | 4,521 | 3,995 | 17,312 | 16,787 |
| Adjusted EBITA margin, % <i>(Adjusted EBITA/Net sales)</i> | 9.8% | 9.1% | 9.7% | 9.5% |

| EBITA growth | Rolling 12 months | Full-year |
|---|--------------------------|------------------|
| | 2025/2026 | 2025 |
| Amounts in SEKm | | |
| Adjusted EBITA | 1,672 | 1,594 |
| Growth, current period compared with previous | 18.2% | 17.1% |

| EBITA margin | 1 January–31 March | | Rolling 12 months | Full-year |
|---------------------|---------------------------|-------------|--------------------------|------------------|
| | 2026 | 2025 | 2025/2026 | 2025 |
| Amounts in SEKm | | | | |
| EBITA | 428 | 311 | 1,507 | 1,390 |
| Net sales | 4,521 | 3,995 | 17,312 | 16,787 |
| EBITA margin | 9.5% | 7.8% | 8.7% | 8.3% |

NOTE 5 Alternative performance measures, cont.

| EBITDA adjusted for leases and items affecting comparability | 1 January–31 March | | Rolling 12 months | Full-year |
|---|---------------------------|-------------|--------------------------|------------------|
| | 2026 | 2025 | 2025/2026 | 2025 |
| Amounts in SEKm | | | | |
| Operating profit (EBIT) | 310 | 237 | 1,082 | 1,009 |
| Depreciation of tangible assets | 121 | 97 | 460 | 435 |
| Amortisation of intangible assets from acquisitions | 89 | 55 | 323 | 288 |
| Amortisation of intangible assets from operating activities | 29 | 19 | 103 | 93 |
| Operating profit (EBITDA) | 549 | 408 | 1,967 | 1,825 |
| Items affecting comparability | 13 | 53 | 165 | 204 |
| Expenses attributable to leases | -94 | -71 | -328 | -305 |
| EBITDA adjusted for leases and items affecting comparability | 469 | 389 | 1,804 | 1,724 |

| Net debt | 31 March | | 31 December |
|--|-----------------|--------------|--------------------|
| | 2026 | 2025 | 2025 |
| Amounts in SEKm | | | |
| Non-current interest-bearing liabilities | 4,242 | 3,320 | 4,223 |
| Non-current interest-bearing liabilities to credit institutions | 4,242 | 3,320 | 4,223 |
| Current interest-bearing liabilities | 574 | 1 | 557 |
| Current interest-bearing liabilities to credit institutions | 574 | 1 | 557 |
| Cash and cash equivalents | 945 | 735 | 884 |
| Net debt | 3,871 | 2,585 | 3,896 |

| Debt/equity ratio | 31 March | | 31 December |
|--------------------------|-----------------|-------------|--------------------|
| | 2026 | 2025 | 2025 |
| Amounts in SEKm | | | |
| Net debt | 3,871 | 2,585 | 3,896 |
| Total equity | 6,871 | 6,239 | 6,588 |
| Debt/equity ratio | 0.6 | 0.4 | 0.6 |

| Net debt/EBITDA adjusted for leases and items affecting comparability | 31 March | | 31 December |
|---|-----------------|-------------|--------------------|
| | 2026 | 2025 | 2025 |
| Amounts in SEKm | | | |
| Net debt | 3,871 | 2,585 | 3,896 |
| EBITDA adjusted for leases and items affecting comparability, rolling 12 months | 1,804 | 1,521 | 1,724 |
| Net debt/EBITDA adjusted for leases and items affecting comparability | 2.15 | 1.70 | 2.26 |
| Outstanding consideration | 187 | - | - |
| Net debt/EBITDA adjusted for leases and items affecting comparability, including outstanding consideration | 2.25 | 1.70 | 2.26 |

| Capital employed | 31 March | | 31 December |
|------------------------------------|-----------------|---------------|--------------------|
| | 2026 | 2025 | 2025 |
| Amounts in SEKm | | | |
| Total equity | 6,871 | 6,239 | 6,588 |
| Total interest-bearing liabilities | 4,928 | 3,322 | 4,781 |
| Contingent considerations | 1,050 | 727 | 870 |
| Compound call and put option | 134 | 118 | 127 |
| Total lease liabilities | 1,091 | 918 | 1,033 |
| Total capital employed | 14,074 | 11,324 | 13,399 |

NOTE 5 Alternative performance measures, cont.

| Return on capital employed | 31 March | | 31 December |
|---|-----------------|--------------|--------------------|
| | 2026 | 2025 | 2025 |
| Amounts in SEKm | | | |
| Operating profit (EBIT), rolling 12 months | 1,082 | 1,008 | 1,009 |
| Average capital employed | 13,143 | 10,158 | 12,456 |
| Return on capital employed, % | 8.2% | 9.9% | 8.1% |
| Goodwill from owner change 2019 | -2,493 | -2,493 | -2,493 |
| Adjusted average capital employed | 10,650 | 7,665 | 9,963 |
| Return on adjusted capital employed, % | 10.2% | 13.2% | 10.1% |

| Net working capital | 31 March | | 31 December |
|---------------------------------|-----------------|--------------|--------------------|
| | 2026 | 2025 | 2025 |
| Amounts in SEKm | | | |
| Inventories | 2,183 | 1,880 | 2,041 |
| Accounts receivable | 2,153 | 1,768 | 2,052 |
| Accounts payable | -1,698 | -1,363 | -1,610 |
| Advance payments from customers | -19 | -34 | -25 |
| Total working capital | 2,619 | 2,250 | 2,459 |

| Return on net working capital (EBITA/NWC), % | 31 March | | 31 December |
|---|-----------------|--------------|--------------------|
| | 2026 | 2025 | 2025 |
| Amounts in SEKm | | | |
| Adjusted EBITA, rolling 12 months | 1,672 | 1,414 | 1,594 |
| Average net working capital | 2,470 | 2,125 | 2,378 |
| Return on net working capital (EBITA/NWC), % | 67.7% | 66.5% | 67.0% |

Earnings per share

Asker has calculated earnings per share in accordance with IAS 33, whereby profit attributable to the Parent Company has been adjusted for the interest component of preference shares, with adjustment being made for the number of common shares received after the conversion of preference shares to common shares in conjunction with the IPO, and the number of

shares has been calculated based on the basis of the average number of shares outstanding. As an alternative performance measure, Asker has calculated earnings per share based on recognised profit or loss for the period, and as if the effects of the new share issue, the set-off issue and the conversion of preference shares to common shares had taken place before the start of the initial comparative period.

| | 1 January–31 March | | Rolling 12 months | Full-year |
|--|---------------------------|-------------|--------------------------|------------------|
| | 2026 | 2025 | 2025/2026 | 2025 |
| Profit or loss attributable to Parent Company's shareholders (SEKm) | 193 | 91 | 593 | 492 |
| Adjustment for interest component of preference shares (SEKm) | – | -31 | – | -31 |
| Adjusted profit or loss attributable to Parent Company's shareholders (SEKm) | 193 | 60 | 593 | 461 |
| Average number of common shares outstanding | 383,036,497 | 323,882,934 | 383,036,497 | 368,248,106 |
| Earnings per share (SEK) | 0.50 | 0.19 | 1.55 | 1.25 |
| Profit or loss attributable to Parent Company's shareholders (SEKm) | 193 | 91 | 593 | 492 |
| Total number of common shares outstanding | 383,036,497 | 383,036,497 | 383,036,497 | 383,036,497 |
| Adjusted earnings per share (SEK) | 0.50 | 0.24 | 1.55 | 1.28 |

Financial key performance indicators

| Amounts in SEKm unless otherwise stated | 2026 | 2025 | | | | 2024 | | | |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | Q1 | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 |
| Net sales | 4,521 | 4,676 | 4,129 | 3,987 | 3,995 | 4,303 | 3,597 | 3,669 | 3,455 |
| EBITA | 428 | 407 | 348 | 323 | 311 | 359 | 272 | 326 | 250 |
| EBITA margin, % | 9.5% | 8.7% | 8.4% | 8.1% | 7.8% | 8.3% | 7.6% | 8.9% | 7.2% |
| Adjusted EBITA | 442 | 470 | 383 | 378 | 364 | 406 | 306 | 338 | 311 |
| Adjusted EBITA margin, % | 9.8% | 10.0% | 9.3% | 9.5% | 9.1% | 9.4% | 8.5% | 9.2% | 8.9% |
| EBITDA adjusted for leases and items affecting comparability | 469 | 511 | 417 | 408 | 389 | 433 | 335 | 364 | 333 |
| Capital employed | 14,074 | 13,399 | 12,780 | 12,321 | 11,324 | 10,247 | 9,894 | 9,169 | 9,150 |
| Average capital employed | 13,143 | 12,456 | 11,668 | 10,946 | 10,158 | 9,615 | 9,211 | 8,901 | 8,810 |
| EBIT | 310 | 281 | 242 | 249 | 237 | 287 | 212 | 271 | 196 |
| Return on capital employed, % | 8.2% | 8.1% | 8.7% | 9.0% | 9.9% | 10.0% | 8.2% | 7.5% | 6.7% |
| Return on adjusted capital employed, % | 10.2% | 10.1% | 11.1% | 11.7% | 13.2% | 13.6% | 11.2% | 10.5% | 9.4% |
| Total assets | 17,753 | 16,774 | 15,937 | 15,208 | 14,234 | 13,118 | 12,631 | 11,825 | 11,802 |
| Equity | 6,871 | 6,588 | 6,509 | 6,424 | 6,239 | 3,502 | 3,356 | 3,297 | 3,222 |
| Profit for the period | 197 | 136 | 146 | 133 | 95 | 108 | 82 | 117 | 69 |
| Net debt | 3,871 | 3,896 | 3,648 | 2,886 | 2,585 | 3,091 | 3,113 | 2,702 | 2,786 |
| Net debt/EBITDA adjusted for leases and items affecting comparability | 2.1 | 2.3 | 2.2 | 1.8 | 1.7 | 2.1 | 2.2 | 2.1 | 2.2 |
| Debt/equity ratio | 0.6 | 0.6 | 0.6 | 0.4 | 0.4 | 0.9 | 0.9 | 0.8 | 0.9 |
| Net working capital | 2,619 | 2,459 | 2,425 | 2,380 | 2,250 | 2,157 | 2,112 | 1,982 | 1,831 |
| Average net working capital | 2,470 | 2,378 | 2,303 | 2,225 | 2,125 | 2,020 | 1,917 | 1,846 | 1,816 |
| Return on net working capital (EBITA/NWC), % | 67.7% | 67.0% | 66.5% | 65.4% | 66.5% | 67.4% | 66.3% | 65.6% | 63.7% |
| Cash flow from operating activities | 419 | 568 | 439 | 211 | 109 | 459 | 223 | 308 | 237 |

| Amounts in SEKm unless otherwise stated | 1 January–31 March | | Rolling 12 months | Full-year |
|---|--------------------|--------|-------------------|-----------|
| | 2026 | 2025 | 2025/2026 | 2025 |
| Net sales | 4,521 | 3,995 | 17,312 | 16,787 |
| EBITA | 428 | 311 | 1,507 | 1,390 |
| EBITA margin, % | 9.5% | 7.8% | 8.7% | 8.3% |
| Adjusted EBITA | 442 | 364 | 1,672 | 1,594 |
| Adjusted EBITA margin, % | 9.8% | 9.1% | 9.7% | 9.5% |
| EBITDA adjusted for leases and items affecting comparability | 469 | 389 | 1,804 | 1,724 |
| Average capital employed | 13,143 | 10,158 | 13,144 | 12,456 |
| Return on capital employed, % | 8.2% | 9.9% | 8.2% | 8.1% |
| Net debt | 3,871 | 2,585 | 3,871 | 3,896 |
| Net debt/EBITDA adjusted for leases and items affecting comparability | 2.1 | 1.7 | 2.1 | 2.3 |
| Debt/equity ratio | 0.6 | 0.4 | 0.6 | 0.6 |
| Average net working capital | 2,470 | 2,125 | 2,470 | 2,378 |
| Return on net working capital (EBITA/NWC), % | 67.7% | 66.5% | 67.7% | 67.0% |
| Average number of full-time equivalents | 3,999 | 3,554 | 3,806 | 3,712 |
| Number of employees at the end of the period | 4,781 | 4,220 | 4,781 | 4,580 |
| Cash flow from operating activities | 419 | 109 | 1,637 | 1,328 |
| Earnings per share before and after dilution (SEK) | 0.50 | 0.19 | 1.55 | 1.25 |
| Earnings per share before and after dilution (SEK), adjusted* | 0.50 | 0.24 | 1.55 | 1.28 |

* Refer to Note 5 for the calculation of alternative performance measures.

Definitions

| KEY PERFORMANCE INDICATORS | DEFINITIONS | PURPOSE |
|--|--|---|
| EBITA | Operating profit before amortisation and impairment of intangible assets. | EBITA provides an overall view of profit generated by operations and is a metric that the Group considers to be relevant for investors who want to understand earnings generation before amortisation of intangible assets. |
| EBITA margin, % | EBITA as a percentage of net sales. | The KPI is used to measure the company's profitability before amortisation and impairment of intangible assets. |
| Items affecting comparability | Acquisition and integration expenses, revaluation of contingent considerations, as well as other non-recurring items deemed to affect comparability. | Items affecting comparability make adjustments for items that are not deemed to reflect the underlying operations. |
| Adjusted EBITA | EBITA excluding items affecting comparability. | The KPI increases comparability of EBITA over time since it makes adjustments for the impact of items affecting comparability that are considered to be of a non-recurring nature and therefore do not reflect the underlying operations. |
| Adjusted EBITA margin, % | Adjusted EBITA as a percentage of net sales. | The KPI is used to measure the company's profitability excluding the impact of acquisition and integration expenses and other items affecting comparability. |
| Organic growth | Year-on-year change in net sales or profit/loss, excluding exchange rate effects, from entities that have been part of the Group for at least 12 months. Growth that arises when Group companies take over specific assets (asset acquisitions) from other operators is normally considered organic growth. This could take the form of the Group taking over distribution contracts and paying a compensation fee to a previous operator. | Organic growth is used to illustrate growth from the underlying business operations adjusted for the effects of currency and acquisitions. |
| EBITA growth | Percentage change in EBITA between two periods. | The KPI is used to measure the company's earnings growth. |
| EBITDA adjusted for leases and items affecting comparability | Operating profit before depreciation, amortisation and impairment of tangible and intangible assets less actual rent costs attributable to leases and items affecting comparability. | The metric shows the company's earnings generation before investments in non-current assets as if all leases had been recognised as operating leases and adjusted for acquisition and integration expenses and other items affecting comparability. |
| Capital employed | Equity and interest-bearing liabilities including contingent considerations and liabilities related to compound call and put options. | Capital employed is a metric that the Group considers to be relevant for investors who want to understand the company's net assets that are to generate profit. |
| Adjusted capital employed | Equity and interest-bearing liabilities including contingent considerations and liabilities related to combined call and put options less the goodwill arising from the change of ownership in 2019. | The metric adjusts capital employed by the goodwill that arose from the change of ownership in 2019 to better reflect the capital of the underlying operations. |
| Average capital employed/adjusted capital employed | Average capital employed/adjusted capital employed for the four most recent quarters. | The measure provides an understanding of capital employed/adjusted capital employed over time and is used to calculate the return on capital employed. |
| Return on capital employed/adjusted capital employed, % | Operating profit (EBIT) rolling 12 months as a percentage of average capital employed/adjusted capital employed. | The metric is an indication of how efficient the Group is at utilising its capital resources. |
| Net debt | Non-current and current interest-bearing liabilities to credit institutions less cash and cash equivalents. | This KPI is used as a supplement to assess the feasibility of paying dividends and making strategic investments, and for assessing the Group's ability to meet its financial commitments. |
| Net debt/EBITDA adjusted for leases and items affecting comparability | Net debt as a percentage of EBITDA less actual rent costs attributable to leases and items affecting comparability, rolling 12 months. | This KPI is a debt ratio that shows how many years it would take to pay off the company's debt, provided that its net debt and EBITDA are constant and without taking into account cash flows for interest, tax and investments. |
| Debt/equity ratio | Net debt as a percentage of equity. | The metric shows the proportion of net debt as a percentage of equity. |
| Net working capital | Total of inventories and accounts receivable less accounts payable and advance payments from customers. | This metric shows the capital that the company has available to finance the operating activities. |
| Average net working capital | Total of inventories and accounts receivable less accounts payable and advance payments from customers, average for the four most recent quarters. | The measure provides an understanding of working capital over time and is used to calculate the return on net working capital. |
| Return on net working capital (EBITA/NWC), % | Adjusted EBITA rolling 12 months as a percentage of average net working capital. | The KPI is used to analyse profitability and is a metric that puts a premium on high EBITA and low net working capital requirements. |

| KEY PERFORMANCE INDICATORS | DEFINITIONS | PURPOSE |
|---|--|--|
| Cash flow from operating activities | Total of cash flow for the period from operating activities. | Cash flow is used to provide an overview of the cash and cash equivalents that flow in and out of the operations. |
| Average number of full-time equivalents | Calculated as the average number of employees for the year, taking into account the percentage of full-time employment. | The metric can be used to compare specific key performance indicators in relation to average employees. |
| Number of employees at the end of the period | The number of employees in the Group at the end of the period. | This metric is used to know how many employees the Group has at the end of a given period. |
| Earnings per share | Profit for the period, adjusted for the amount related to the settlement of preference shares, attributable to the Parent Company's shareholders divided by the average number of common shares outstanding. | Earnings per share is used to determine the value of the company's average number of common shares outstanding. |
| Adjusted earnings per share | Recognised profit for the period attributable to the Parent Company's shareholders divided by the total number of common shares outstanding. | Adjusted earnings per share is used to determine the value of the company's total number of common shares outstanding. |

About Asker Healthcare Group

**Leading provider of medical products and solutions –
Driving progress in the European healthcare sector.**


Asker Healthcare Group is a European leading provider of medical products and solutions.

Over the past decade we have organically and via acquisitions built a pan-European group with deep knowledge in healthcare, attracting entrepreneurs that together with us want to drive progress and support the healthcare sector to improve patient outcomes, reduce the total cost of care and ensure a fair and sustainable value chain.

By combining entrepreneurial responsibility with a distinct steering model, we have created a solid platform for growth with continuous acquisitions in the large and fragmented European market.

Today, the Group consists of more than 50 companies in 19 countries and more than 5,000 employees, and brings significant scale and knowledge sharing, to the benefit of the Group and the healthcare sector.

We are “Health in progress”.



Financial calendar

| | Date |
|-----------------------------|-----------------|
| Annual General Meeting 2026 | 7 May 2026 |
| Interim Report – Q2 2026 | 21 July 2026 |
| Interim Report – Q3 2026 | 4 November 2026 |

Additional information

Investors and analysts

Thomas Moss, CFO and Head of IR
Tel: +46 70 219 79 05
E-mail: ir@asker.com

Media

Emma Rheborg, Head of Communication,
Tel: +46 73 313 62 17
E-mail: emma.rheborg@asker.com

The information was submitted for publication, through the agency of the contact persons set out above, on 6 May 2026, at 8:10 a.m. CEST.



Address: Asker Healthcare Group AB
Svärdvägen 3A, SE-182 33 Danderyd, Sweden
www.asker.com